May 17-18, 2023
2-Day Digital Conference8:00AM PDT // 11:00AM EDT // 4:00PM BSTKey Sessions
Gabriele Allegri
Conversation With Big Pharma; Get on Board With Precision Medicine Investments
The Janssen Pharmaceutical Companies of Johnson & Johnson, USA
Jeffrey M. Bockman
How to Adapt Your R&D and Clinical Strategies to Maximise Partnership Opportunity
Lumanity, USA
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
May 17 - MT (Mexican Pacific Time, GMT-07:00)
keyboard_arrow_leftSearch & Filter
search
Formats
Topics
May 17 - MT (Mexican Pacific Time, GMT-07:00)
search
Formats
Topics
Showing 1 of 1 Streams
Day 1 - Therapeutic Area Partnerships Oncology 2023
08:00 - 08:05
Welcoming Remarks
- Patrick Murphy - Digital Events Conference Producer, Informa Connect, UK
08:05 - 08:35
Evaluation of Multi-Cancer Early Detection Technology
- Insight into the market of early detection technology and analysis of future growth
- Understand the technology that can detect a tumour before it has formed
- Unveil the opportunities and limitations of multi-cancer early detection
- Conversation on using multi-cancer early detection technology as a vehicle for therapeutic development
- Hadly Clark - Associate Director, FasterCures, a Centre of the Milken Institute, USA
08:35 - 09:05
Invest to Stop Invasiveness During Ovarian Cancer Diagnosis
- Learn about the liquid biopsies revolutionizing cancer diagnostics
- Get insight into the upcoming wave of new essential biomarkers for cancer diagnosis
- Invest to help save half the women diagnosed with cancer
- Hear from an expert with a decade of experience in large strategic exits and commercialization across global markets
- Oriana Papin-Zoghbi - CEO and Co-founder, AOADX, USA
09:05 - 10:05
Discussion on The Future of Cancer Diagnostics. What Role Will Liquid Biopsies Play?
- How prevalent will liquid biopsies be in the future?
- Will liquid biopsies be successful?
- How can liquid biopsies be adapted to detect all cancer types?
- What does the business and commercialization strategy of liquid biopsies look like?
- What major issues do liquid biopsies face?
- Are liquid biopsies a good investment?
- Alessandra Cesano - Chief Medical Officer, ESSA Pharmaceuticals, USA
- Tom Miller - Founding & Managing Partner, GreyBird Ventures, LLC, USA
- Hadly Clark - Associate Director, FasterCures, a Centre of the Milken Institute, USA
- Dan Milner - Consultant Pathologist, American Society for Clinical Pathology, USA
10:05 - 10:30
Break & Networking
Make the most of your digital experience and utilise our platform during the break:
- Organize 1-2-1 meetings with fellow attendees with the option to video chat
- Expand your network and talk with the experts of women's health
- Ask speakers about their presentations
10:30 - 11:00
Multi-Cancer Early Detection for Non-Traditional Markets: A Mutual Beneficial Approach to Leapfrogging the Field
- Discover the incredible power of MCED in low resources settings to transform health systems
- Help save billions of dollars
- Massively increase the access to therapeutics
- Dan Milner - Consultant Pathologist, American Society for Clinical Pathology, USA
11:00 - 11:30
Discussion With The Pros of Next-Generation Sequencing. Is Precision Medicine The Way Forward?
- Understand how the newest sequencing capabilities and most advanced AI are providing novel insights
- A balanced discussion on whether prioritising precision care is the best option
- Transition your investment portfolio from volume-based to value-based care
- Partnership opportunity with one of industries biggest game changers
11:30 - 12:00
Conversation With Big Pharma; Get on Board With Precision Medicine Investments
- Get insight into the future business strategy of the market leaders
- Realize all the opportunities awaiting from investing in personalized medicine
- Hear case studies into previous and potential future collaborations in the space
- Gabriele Allegri - Global Commercial Head - Precision Medicine, The Janssen Pharmaceutical Companies of Johnson & Johnson, USA
12:00 - 12:30
Break & Networking
Make the most of your digital experience and utilise our platform during the break:
- Organize 1-2-1 meetings with fellow attendees with the option to video chat
- Expand your network and talk with the experts of women's health
- Ask speakers about their presentations
12:30 - 13:00
How to Adapt Your R&D and Clinical Strategies to Maximise Partnership Opportunity
- Get consulted on how to make the best decisions in building up your therapeutics report
- Learn to evolve & adapt to suit the current needs of big pharma
- Acquire new skills and experiences to add to your own arsenal to take on the partnership space and get your therapeutic pipeline licensed
- Jeffrey M. Bockman - Executive Vice President, BioConsulting and Head of Oncology, Lumanity, USA
13:00 - 13:30
A preventative Medication to Address The Disabling and Treatment Limiting Impact of Chemotherapy Induced Peripheral Neuropathy (CIPN)
- Marked impact of CIPN on patients’ quality of life that can prohibit optimal chemotherapy treatment intensity
- No available agents approved for prevention or acute treatment
- Disproportionate impact on breast cancer patients
- A novel mechanism entering the clinic to prevent CIPN
- Bob Linke - CEO, Osmol Therapeutics, USA
- Barbara Ehrlich - Professor of Pharmacology, Yale School of Medicine, Yale School of Medicine, USA
13:30 - 14:00
Partner With The Digital Clinic Revolutionising Cancer Survivor Patient Care
- Hear the story of a breast cancer survivor
- Unique insight into an innovative digital clinic before it hits the market
- Help cancer survivors live healthier, better and happier lives
- Hil Moss - Co-Founder/Chief Executive Officer, VivorCare, USA
Filter
Formats
Topics